Ivermectin In Treatment of COVID 19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-09

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ivermectin in Treatment of COVID-19

NCT04445311

COVID

UNKNOWN PHASE2/PHASE3

The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment

NCT04351347

COVID

RECRUITING PHASE2/PHASE3

New Antiviral Drugs for Treatment of COVID-19

NCT04392427

COVID Drug Effect

UNKNOWN PHASE3

Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic

NCT04668469

Covid19

COMPLETED NA

Ivermectin Role in Covid-19 Clinical Trial

NCT04746365

Covid19

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A ivermectin alone

ivermectin will be administarted alone to COVID 19 patients

Group Type EXPERIMENTAL

Ivermectin

Intervention Type DRUG

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

B standard care alone

standard care will be administarted alone

Group Type EXPERIMENTAL

Ivermectin

Intervention Type DRUG

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

C ivermectin added to standard of care

ivermectin will be administarted in adition to standard care

Group Type ACTIVE_COMPARATOR

Ivermectin

Intervention Type DRUG

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivermectin

use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hydroxychloroquine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Exclusion Criteria

* Contraindications for the drug: hypersensitivity.
* Any medications with possible drug interactions.
* Severe cases.
* Any malignant condition.
* Pregnant females.
* Breast feeding females.
* Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No